205 related articles for article (PubMed ID: 33760143)
1. Cyanidin‑3‑O‑β‑glucoside protects against pulmonary artery hypertension induced by monocrotaline via the TGF‑β1/p38 MAPK/CREB signaling pathway.
Ouyang S; Chen W; Gaofeng Z; Changcheng L; Guoping T; Minyan Z; Yang L; Min Y; Luo J
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760143
[TBL] [Abstract][Full Text] [Related]
2. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
[TBL] [Abstract][Full Text] [Related]
3. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
[TBL] [Abstract][Full Text] [Related]
4. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
5. Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways.
Yu M; Wu X; Wang J; He M; Han H; Hu S; Xu J; Yang M; Tan Q; Wang Y; Wang H; Xie W; Kong H
Int J Med Sci; 2022; 19(4):681-694. PubMed ID: 35582418
[TBL] [Abstract][Full Text] [Related]
6. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.
Luan Y; Chao S; Ju ZY; Wang J; Xue X; Qi TG; Cheng GH; Kong F
Int Immunopharmacol; 2015 May; 26(1):188-93. PubMed ID: 25601497
[TBL] [Abstract][Full Text] [Related]
8. Notch4 mediates vascular remodeling via ERK/JNK/P38 MAPK signaling pathways in hypoxic pulmonary hypertension.
Guo M; Zhang M; Cao X; Fang X; Li K; Qin L; He Y; Zhao J; Xu Y; Liu X; Li X
Respir Res; 2022 Jan; 23(1):6. PubMed ID: 35016680
[TBL] [Abstract][Full Text] [Related]
9. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
11. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta1 upregulation triggers pulmonary artery smooth muscle cell proliferation and apoptosis imbalance in rats with hypoxic pulmonary hypertension via the PTEN/AKT pathways.
Liu Y; Cao Y; Sun S; Zhu J; Gao S; Pang J; Zhu D; Sun Z
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):141-154. PubMed ID: 27297622
[TBL] [Abstract][Full Text] [Related]
13. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
[TBL] [Abstract][Full Text] [Related]
14. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.
Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J
Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325
[TBL] [Abstract][Full Text] [Related]
15. Capsaicin pretreatment reversed pulmonary arterial hypertension by alleviating inflammation via p38MAPK pathway.
Xu Y; Gu Q; Qu C
Exp Lung Res; 2017 Feb; 43(1):8-18. PubMed ID: 28281854
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
17. Heparin reduces overcirculation-induced pulmonary artery remodeling through p38 MAPK in piglet.
Zhao G; Seng J; Beagle J; Syrkina O; Hales CA
Ann Thorac Surg; 2015 May; 99(5):1677-84. PubMed ID: 25818573
[TBL] [Abstract][Full Text] [Related]
18. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
19. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
[TBL] [Abstract][Full Text] [Related]
20. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
